Annals of surgical oncology · 2026
Examining the Representation of Minority Race and Ethnicity Groups in Breast Cancer Clinical Trials in the USA Published 2012-2022.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dimaano Katrina, Castillo Otilio, Moazzez Ashkan, Ozao-Choy Junko, Dauphine Christine
Аннотация
BACKGROUND: Diversity of study populations in clinical trials is essential to addressing health outcome disparities in cancer care. The objective of this study was to examine the inclusion of minority race/ethnicity groups in breast cancer clinical trials published in the United States of America (USA) 2012-2022.
PATIENTS AND METHODS: Breast cancer clinical trials published as a full manuscript in the USA 2012-2022 were identified. Trial characteristics and race/ethnicity of subjects were collected to assess the degree of reporting and inclusion of minority populations. Participation to Prevalence Ratios (PPRs) were utilized as a measure of inclusion.
RESULTS: In 1068 trials (n = 871,683 subjects), race/ethnicity was reported in 785 (73.5%), increasing from 2012 to 2016 (68.8%) to 2017 to 2022 (79.3%, p < 0.001). Higher rates of race/ethnicity reporting were independently associated with later publication year, randomized or phase II trials, and those reporting social determinants of health. Of the 732,969 subjects for whom race/ethnicity was reported, 16,551 (2.3%) were Asian American/Pacific Islander (Asian), 43,288 (5.9%) were Black/African American, 22,464 (3.1%) were Hispanic/Latinx, and 570,897 (77.9%) were Non-Hispanic White. A PPR above 0.8 was achieved in 27.3% of trials that reported race for Asian subjects, 44.7% for Black/African American subjects, 27.4% for Hispanic/Latinx subjects, and in 5.7% for all three minority groups. All four primary race groups in the USA were represented in 24.7% of trials, and race/ethnicity was included as a factor in outcome analysis in 8.7%.
CONCLUSIONS: Although race/ethnicity reporting has improved, minority populations remain gravely underrepresented in breast cancer clinical trials, limiting the generalizability of trial results in these populations.
PATIENTS AND METHODS: Breast cancer clinical trials published as a full manuscript in the USA 2012-2022 were identified. Trial characteristics and race/ethnicity of subjects were collected to assess the degree of reporting and inclusion of minority populations. Participation to Prevalence Ratios (PPRs) were utilized as a measure of inclusion.
RESULTS: In 1068 trials (n = 871,683 subjects), race/ethnicity was reported in 785 (73.5%), increasing from 2012 to 2016 (68.8%) to 2017 to 2022 (79.3%, p < 0.001). Higher rates of race/ethnicity reporting were independently associated with later publication year, randomized or phase II trials, and those reporting social determinants of health. Of the 732,969 subjects for whom race/ethnicity was reported, 16,551 (2.3%) were Asian American/Pacific Islander (Asian), 43,288 (5.9%) were Black/African American, 22,464 (3.1%) were Hispanic/Latinx, and 570,897 (77.9%) were Non-Hispanic White. A PPR above 0.8 was achieved in 27.3% of trials that reported race for Asian subjects, 44.7% for Black/African American subjects, 27.4% for Hispanic/Latinx subjects, and in 5.7% for all three minority groups. All four primary race groups in the USA were represented in 24.7% of trials, and race/ethnicity was included as a factor in outcome analysis in 8.7%.
CONCLUSIONS: Although race/ethnicity reporting has improved, minority populations remain gravely underrepresented in breast cancer clinical trials, limiting the generalizability of trial results in these populations.